PN,30501
SC,0001
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FBladder cancer patients given an
OL,8,Fimmunotherapy drug are a third less
OL,9,Flikely to see disease come back and
OL,10,Fare more likely to survive, according
OL,11,Fto a "game-changer" study.
OL,13,FPatients with advanced (muscle-
OL,14,Finvasive) bladder cancer had
OL,15,Fsignificantly less risk of cancer
OL,16,Fprogressing or returning when treated
OL,17,Fwith durvalumab, and were more likely
OL,18,Fto still be alive two years after
OL,19,Ftreatment.
OL,26,@sD@FOUsD@SO]
OL,1,W~k4~sj5j5~s1G                    G1/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30502
SC,0002
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FExperts from the University of
OL,8,FSheffield and Barts Cancer Institute
OL,9,Fat Queen Mary University of London
OL,10,Fincluded 1,063 patients with operable
OL,11,Fbladder cancer in their study.
OL,13,FPatients were given either standard
OL,14,Fchemotherapy (cisplatin and
OL,15,Fgemcitabine) and surgery (530 people),
OL,16,For chemotherapy plus durvalumab before
OL,17,Fsurgery and eight cycles of durvalumab
OL,18,Fafter surgery (533).
OL,1,W~k4~sj5j5~s1G                    G2/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30503
SC,0003
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FThe final-stage phase 3 clinical trial
OL,8,Ffound patients were 32% less likely to
OL,9,Fexperience cancer recurrence or
OL,10,Fprogression if they had immunotherapy,
OL,11,Fand were more likely to still be alive
OL,12,Fafter two years.
OL,14,FOverall survival at two years was
OL,15,F82.2% in the durvalumab group and
OL,16,F75.2% in the comparator group.
OL,18,FDurvalumab (brand name Imfinzi) is a
OL,19,Ftreatment for non small cell lung
OL,20,Fcancer (NSCLC) but is also being
OL,21,Ftrialled in other cancers.
OL,1,W~k4~sj5j5~s1G                    G3/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30504
SC,0004
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FJames Catto, professor of urology at
OL,8,Fthe University of Sheffield and
OL,9,Fhonorary consultant urological
OL,10,Fsurgeon, who co-led the study, said:
OL,11,F"This is a major breakthrough in the
OL,12,Ftreatment of bladder cancer.
OL,14,F"For many years, survival rates for
OL,15,Fadvanced bladder cancer have remained
OL,16,Fstagnant, but our findings offer hope
OL,17,Fto thousands of patients who face this
OL,18,Fdevastating diagnosis.
OL,26,@sD@AOUvD@AOU
OL,1,W~k4~sj5j5~s1G                    G4/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30505
SC,0005
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,F"Patients treated with durvalumab
OL,8,Fbefore and after surgery had both
OL,9,Fsignificantly higher survival rates
OL,10,Fand lower risks of the cancer
OL,11,Freturning and didn't face any
OL,12,Fadditional serious side effects.
OL,14,F"This is important for patients
OL,15,Fundergoing chemotherapy and its
OL,16,Fnumerous and often debilitating side
OL,17,Feffects.
OL,26,@oD@AOUvD@AOU
OL,1,W~k4~sj5j5~s1G                    G5/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30506
SC,0006
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,F"Our hope is that this treatment can
OL,8,Fbe made available for NHS patients as
OL,9,Fsoon as possible following regulatory
OL,10,Fapproval by the Medicines and
OL,11,FHealthcare products Regulatory Agency,
OL,12,Fand that it becomes the new standard
OL,13,Fof care.
OL,15,F"Recent research suggests that cases
OL,16,Fof bladder cancer will increase by 50%
OL,17,Fover the next two decades, but yet the
OL,18,Flevel of awareness about bladder
OL,19,Fcancer in the UK remains low."
OL,26,@oD@AOUwD@AOU{D@^O]
OL,1,W~k4~sj5j5~s1G                    G6/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30507
SC,0007
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FThe trial was funded by AstraZeneca,
OL,8,Fwith the results published in the New
OL,9,FEngland Journal of Medicine.
OL,11,FAt the the moment, around half of
OL,12,Fpatients with muscle-invasive bladder
OL,13,Fcancer experience recurrence within
OL,14,Fthree years.
OL,1,W~k4~sj5j5~s1G                    G7/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30508
SC,0008
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FSyed Hussain, professor and honorary
OL,8,Fconsultant of medical oncology at the
OL,9,FUniversity of Sheffield and Sheffield
OL,10,FHospitals NHS Foundation Trust and
OL,11,Fprincipal investigator of the trial,
OL,12,Fsaid the "magnitude of survival
OL,13,Fbenefit seen will certainly be a game
OL,14,Fchanger".
OL,16,FHe added: "These are exciting times in
OL,17,Fthe management of muscle-invasive
OL,18,Fbladder cancer.
OL,26,@tD@JOUvD@HO]xD@KOU
OL,1,W~k4~sj5j5~s1G                    G8/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30509
SC,0009
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,F"We had not seen any additional
OL,8,Fsurvival benefit in previous trials
OL,9,Finvestigating additional treatments in
OL,10,Fcombination with standard of care
OL,11,Fcisplatin-based chemotherapy before
OL,12,Fsurgery.
OL,14,F"By bringing these exciting new
OL,15,Ftreatments earlier in the disease
OL,16,Fpathway we will continue to see more
OL,17,Fpatients being cured of muscle-
OL,18,Finvasive bladder cancer."
OL,26,@oD@AOUvD@AOUzD@YO]
OL,1,W~k4~sj5j5~s1G                    G9/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30510
SC,0010
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FLead author of the study, Thomas
OL,8,FPowles, professor of genitourinary
OL,9,Foncology at Queen Mary University of
OL,10,FLondon's Barts Cancer Institute, said:
OL,11,F"In (the) NIAGARA (trial), we showed
OL,12,Ffor the first time that the addition
OL,13,Fof immunotherapy to chemotherapy
OL,14,Fincreases the rate of overall
OL,15,Fsurvival. This is a major step forward
OL,16,Ffor these patients."
OL,26,@sD@AOUxD@TO]
OL,1,W~k4~sj5j5~s1G                   G10/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
PN,30511
SC,0011
CT,2,C
PS,c008
OL,0,        ECIMSBWebfax     F305A1736742469
OL,3,C'Increased survival rates' for bladder
OL,4,Ccancer patients given immunotherapy
OL,5,Cdrug
OL,7,FIan Flower, 63, from Sheffield took
OL,8,Fpart in the NIAGARA trial, which was
OL,9,Frun at Sheffield Teaching Hospitals
OL,10,FNHS Foundation Trust, after being
OL,11,Fdiagnosed with operable bladder cancer.
OL,13,F"I was happy to help with the trial,
OL,14,Fnot just for myself but in the hope
OL,15,Fthat it could help other patients," he
OL,16,Fsaid.
OL,18,F"It is nice to hear the trial received
OL,19,Fpositive results and I hope it can
OL,20,Fbecome available for other patients."
OL,26,@uD@AOUwD@cO]zD@AOU|D@eO]
OL,1,W~k4~sj5j5~s1G                   G11/11
OL,2,W/*%+,"-/.!,.!T,,,,,,,,,,,,,,,,,,,,,,,,,
OL,23,TppppppppppppppppppGsource: itv.com/news
OL,24,ANext Page BNat News CNat TV FClean Feed
FL,306,300,200,140,000,100
